The survey of the following epidemiologic studies of "Institut fUr Arterioskle roseforschung" in MUnster was given: 1. Follow-up study to analyze longterm mortality after myocardial infarction and individual risk of death. 2. Secondary preventive study after myocardial infarction under the conception of mesenchymal suppression. 3. Prospective study to find out the predictive power of cholesterol sub fractions. 4. Study of old age probands. The advantage of our infrastructure of the epidemiologic work lies in the close connection to the clinical medicine, as the scientific planning and guidance is done by physicians and teachers of university clinic. There is less danger that irrelevant problems are followed or that non-medical researchers like statisticians will domi nate the studies. We have deliberately avoided to join or organize multicenter stu dies believing that a larger output of data cannot outweigh the disadvantages of possible mistakes and errors through lack of contact and controversial conceptions among the coworkers. We hope to show that studies planned for screening of as many as 10 000 probands can be performed at relatively low expense. An im portant point is the adaptability of our system, which enables us to enlarge the already running studies for instance by addition of parameters like blood coagula tion as is being prepared by the team of Professor van de Loo in MUnster. References 1. Assmann, G. , Oberwittier, W. , Schulte, H. , Schriewer, H. , Funke, H. , Epping, P. H.

Klappentext

The survey of the following epidemiologic studies of "Institut fUr Arterioskle­ roseforschung" in MUnster was given: 1. Follow-up study to analyze longterm mortality after myocardial infarction and individual risk of death. 2. Secondary preventive study after myocardial infarction under the conception of mesenchymal suppression. 3. Prospective study to find out the predictive power of cholesterol sub fractions. 4. Study of old age probands. The advantage of our infrastructure of the epidemiologic work lies in the close connection to the clinical medicine, as the scientific planning and guidance is done by physicians and teachers of university clinic. There is less danger that irrelevant problems are followed or that non-medical researchers like statisticians will domi­ nate the studies. We have deliberately avoided to join or organize multicenter stu­ dies believing that a larger output of data cannot outweigh the disadvantages of possible mistakes and errors through lack of contact and controversial conceptions among the coworkers. We hope to show that studies planned for screening of as many as 10 000 probands can be performed at relatively low expense. An im­ portant point is the adaptability of our system, which enables us to enlarge the already running studies for instance by addition of parameters like blood coagula­ tion as is being prepared by the team of Professor van de Loo in MUnster. References 1. Assmann, G. , Oberwittier, W. , Schulte, H. , Schriewer, H. , Funke, H. , Epping, P. H.

Inhalt
Begrüssung.- Prof. Dr. Ludwig E. Feinendegen.- Prof. Dr. Heinz Schröer.- Prof. Dr. Harald Feldmann.- Direktor Otto Heller.- 1 Primary Prevention of Cardiovascular Disease. Recent Trials.- 2 Secondary Trials after Myocardial Infarction: A Review.- 3 Münster Studies of Coronary Heart Disease.- 4 Prediction and Early Detection of Coronary Heart Disease.- 5 Progression of Coronary Artery Disease as Judged from Sequential Angiography.- 6 New Non-Invasive Ways to Measure Plaque Size, their Development and Implications.- 7 Endothelial Injury and Repair.- 8 Extracellular Matrix Proteins of the Vessel Wall: Are they Possible Markers of Atherosclerotic Processes?.- 9 External Measuring of Myocardial Structure and Function.- 10 Immunological Anomalies in High Risk Women on the Pill.- 11 Diet in Experimental Atherosclerosis.- 12 Cardiovascular Effects of Exercise in Primate Atherosclerosis.- 13 Prostacyclin and Atherosclerosis Experimental and Clinical Approach.- 14 Antirheumatic Drugs and their Influence on Arterial Wall Cells of Normal and Injured Animals.- 15 Effects of Alfalfa Saponins on Regression of Atherosclerosis in Monkeys.- 16 The Effect of Alcohol on Human Platelet Function. The Role of Platelet Membrane and Plasma Lipids.- 17 Effect of the Anthocyanosides of Vaccinium myrtillus on the Vascular Wall.- 18 Growth Factors and Atherogenesis.- 19 Significance of Coagulation in Atherogenesis.- 20 Contribution of Blood Platelets to the Pathogenesis of Myocardial Infarction.- 21 Isovolemic Hemodilution as a Functional Therapy of Decompensated Arteriosclerotic Stenoses of the Femoral, Cerebral and Ophthalmic Artery.- 24 The Role of HDL Cholesterol in Preventive Medicine.- 25 LDL and HDL in Human Arteries Role in Atherogenesis.- 26 A New Tracer for the Metabolic Fateof Cholesteryl Ester.- 27 The Latest Evidence, in vitro and in vivo, on Controlling Smooth Muscle Cell Proliferation and Arterial Wall Cholesterol Ester Accumulation by Controlling LDL Concentration.- 28 Summary Chapter.- 29 Final Remarks.